Partnership Focused on Developing Drugs Targeting the Th17 Pathway through the Inhibition of RORγt to Treat Autoimmune Diseases ANN ARBOR, Mich. – December 21, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research… Read More

ANN ARBOR, Mich. – October 4, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Kathleen M. Metters, Ph.D., former senior vice president and head of worldwide basic research at Merck, has been named president and chief executive officer and a member… Read More

PLYMOUTH, Mich. – September 7, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company will present at the following industry conferences this fall: BioPharm America™ 2011, being held Sept. 7-9 at the Westin Boston Waterfront in Boston. Gary D. Glick,… Read More

PLYMOUTH, Mich. – March 27, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company presented at the following industry conferences: Society for Biomolecular Sciences (SBS) 17th Annual Conference and Exhibition, held March 27-31 in Orlando, Fla. Xiao Hu, Ph.D., senior… Read More

Companies to Focus on Developing Drugs that Inhibit RORγt PLYMOUTH, Mich. – March 3, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target… Read More

Findings Demonstrate Lycera’s Compound Selectively Silences Pathogenic Cells and Arrests Graft-Versus-Host Disease PLYMOUTH, Mich. – January 26, 2011 – Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced positive data from the University of Michigan demonstrating the role of bioenergetics in selectively inhibiting pathogenic… Read More

Significant Progress Made in Advancing Company’s Small Molecules for the Treatment of Autoimmune Diseases; Appoints Chairman of the Board and Welcomes New Vice President in Preparation for Clinic Ann Arbor, Mich., and Cambridge, Mass. – April 28, 2010 — Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat… Read More

Former Head of U.S. Commercial at Biogen Idec Will Lead Emerging Small Molecule Immunology Company in Next Phase of Growth Ann Arbor, Mich., and Cambridge, Mass. – January 7, 2010 — Lycera Corporation, a pharmaceutical company focused on developing novel small-molecule medicines to treat autoimmune diseases, today announced that William J. Sibold has been named… Read More

ANN ARBOR, Mich., October 9, 2009 — Lycera Corp., which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases, today announced the appointments of Paul S. Changelian, Ph.D. and Peter L. Toogood, Ph.D. to the company’s drug development team. Dr. Changelian, previously director of inflammation biology at Pfizer, will serve as vice president of biology.… Read More